Menu
GWAS Study

Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.

Fernandez CA, Smith C, Yang W et al.

25987655 PubMed ID
GWAS Study Type
3308 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

FC
Fernandez CA
SC
Smith C
YW
Yang W
MC
Mullighan CG
QC
Qu C
LE
Larsen E
BW
Bowman WP
LC
Liu C
RL
Ramsey LB
CT
Chang T
KS
Karol SE
LM
Loh ML
RE
Raetz EA
WN
Winick NJ
HS
Hunger SP
CW
Carroll WL
JS
Jeha S
PC
Pui CH
EW
Evans WE
DM
Devidas M
RM
Relling MV
Chapter II

Abstract

Summary of the research findings

Asparaginase is used to treat acute lymphoblastic leukemia (ALL); however, hypersensitivity reactions can lead to suboptimal asparaginase exposure. Our objective was to use a genome-wide approach to identify loci associated with asparaginase hypersensitivity in children with ALL enrolled on St. Jude Children's Research Hospital (SJCRH) protocols Total XIIIA (n = 154), Total XV (n = 498), and Total XVI (n = 271), or Children's Oncology Group protocols POG 9906 (n = 222) and AALL0232 (n = 2163). Germline DNA was genotyped using the Affymetrix 500K, Affymetrix 6.0, or the Illumina Exome BeadChip array. In multivariate logistic regression, the intronic rs6021191 variant in nuclear factor of activated T cells 2 (NFATC2) had the strongest association with hypersensitivity (P = 4.1 × 10(-8); odds ratio [OR] = 3.11). RNA-seq data available from 65 SJCRH ALL tumor samples and 52 Yoruba HapMap samples showed that samples carrying the rs6021191 variant had higher NFATC2 expression compared with noncarriers (P = 1.1 × 10(-3) and 0.03, respectively). The top ranked nonsynonymous polymorphism was rs17885382 in HLA-DRB1 (P = 3.2 × 10(-6); OR = 1.63), which is in near complete linkage disequilibrium with the HLA-DRB1*07:01 allele we previously observed in a candidate gene study. The strongest risk factors for asparaginase allergy are variants within genes regulating the immune response.

3,126 child cases

Chapter III

Study Statistics

Key metrics and study information

3308
Total Participants
GWAS
Study Type
Yes
Replicated
182 child cases
Replication Participants
European, Hispanic or Latin American, African unspecified, Asian unspecified, Other
Ancestry
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.